{"entity":{"id":"paper-keynote-826-nejm-2021","kind":"paper","name":"KEYNOTE-826: pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer","aka":[],"tldr":"Adding pembrolizumab to first-line chemotherapy, with or without bevacizumab, lengthened survival in advanced cervical cancer, the first improvement in the disease since bevacizumab was added seven years earlier.","summary":"Phase 3 placebo-controlled trial of 617 patients with persistent, recurrent or metastatic cervical cancer randomised to pembrolizumab or placebo with platinum-paclitaxel chemotherapy, with bevacizumab at investigator discretion.\n\nIn the PD-L1 combined positive score 1 or more population, median overall survival was not reached versus 16.3 months at the first analysis (hazard ratio 0.64) and 28.6 versus 16.5 months on update; progression-free survival was 10.4 versus 8.2 months.","asOf":"2026-09-17","links":[{"label":"N Engl J Med 2021","url":"https://doi.org/10.1056/NEJMoa2112435"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/34534429/"}],"tags":[],"related":[],"cancers":["recurrent-metastatic-cervical-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["keynote-826"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2021,"doi":"10.1056/NEJMoa2112435","pmid":"34534429","authors":"Colombo N, Dubot C, Lorusso D, et al.","paperType":"rct","findings":["Combined positive score 1 or more: overall survival hazard ratio 0.64; updated median 28.6 vs 16.5 months.","Median progression-free survival 10.4 vs 8.2 months."],"whatItMeans":"Pembrolizumab plus chemotherapy with bevacizumab is the first-line standard for recurrent or metastatic cervical cancer with PD-L1 expression, which covers about nine in ten patients.","caveats":["Benefit in PD-L1-negative tumours was uncertain.","Bevacizumab use was not randomised."],"changedPractice":true,"participants":617},"route":"/key-papers/paper-keynote-826-nejm-2021/","neighbours":{"cancer":[{"id":"recurrent-metastatic-cervical-cancer","kind":"cancer","name":"Recurrent or metastatic cervical cancer","route":"/cancers/recurrent-metastatic-cervical-cancer/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"trial":[{"id":"keynote-826","kind":"trial","name":"KEYNOTE-826","route":"/trials/keynote-826/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}